Anticoagulants for PFO Patients

Xuanwu Hospital, Beijing277 enrolled

Overview

Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August 2023. The patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). In cases with mild-shunt (small-size) PFO, post-procedural anticoagulation or PFO closure was administered. Subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality.

Study Type

OBSERVATIONAL

Enrollment

277

Conditions

Patent Foramen Ovale

Interventions

PFO closurePROCEDURE

PFO closure

anticoagulantDRUG

rivaroxaban

Eligibility

Sex: ALLMin age: 16 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. verified PFO diagnosis through TEE, Bubble-TCD, or contrast echocardiography of the right heart; 2. ages range between 16 and 65; 3. no restrictions on sexual orientation; 4. stroke patients with cryptogenic strokes as per the TOAST classification; 5. no other likely causes for migraines, with the exception of PFO; 6. no multiple risk factors for cerebrovascular disease, such as hypertension, diabetes, or smoking. Exclusion Criteria: * 1)severe, acute, or life-threatening conditions including acute cardio-cerebrovascular diseases, significant organ failure, or infections; 2)magnetic resonance imaging (MRI) contraindications, especially with contrast enhancement; 3) presence of cerebral artery stenosis, internal carotid artery stenosis, or atherosclerosis; 4) hypercoagulability or venous thrombosis; 5) contraindications associated with PFO closure and anticoagulants; 6) obstructive sleep apnea.

Outcomes

Primary Outcomes

whether occur recurrent stroke or migraine relief

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.